Journal Guides8 min readUpdated Mar 25, 2026

Annals of Oncology Acceptance Rate

Annals of Oncology does not publish a strong official acceptance rate. The better submission question is whether the paper is broad and mature enough to matter at ESMO-flagship level.

Senior Researcher, Oncology & Cell Biology

Author context

Specializes in manuscript preparation and peer review strategy for oncology and cell biology, with deep experience evaluating submissions to Nature Medicine, JCO, Cancer Cell, and Cell-family journals.

Journal evaluation

Want the full journal picture?

See scope, selectivity, submission context, and what editors actually want before you decide whether the journal is realistic.

Open Journal GuideAnthropic Privacy Partner. Zero-retention manuscript processing.Run Free Readiness Scan

Quick answer: there is no strong official Annals of Oncology acceptance-rate number you should treat as exact. The better submission question is whether the paper is broad, mature, and clinically consequential enough to matter at ESMO-flagship level.

If the evidence is still early, the clinical consequence is still too local, or the translational bridge still needs explanation, the unofficial percentage is not the real issue. The fit is.

What you can say honestly about the acceptance rate

There is no stable official acceptance-rate figure from the journal or publisher that is strong enough to anchor this query around exact precision.

What is stable is the editorial model:

  • the journal is highly selective about clinical consequence
  • randomized trials, guideline-relevant datasets, and treatment-shaping evidence matter most
  • translational work usually needs a clear bridge to patient care
  • the ESMO flagship identity raises the bar on evidence maturity and relevance

That is the planning surface authors actually need.

What the journal is really screening for

Annals of Oncology is usually asking:

  • will this change clinical interpretation, treatment choice, or guideline-level thinking?
  • is the evidence mature enough to support that consequence?
  • does the paper belong in a broad oncology flagship rather than a narrower specialty title?
  • is the translational or biomarker work tied tightly enough to real patient meaning?

Those are the questions that matter more than a rumored percentage.

The better decision question

For Annals of Oncology, the useful question is:

If this paper is true, does it have enough broad oncology consequence to matter at ESMO-flagship level?

If yes, the journal is plausible. If no, the acceptance-rate discussion is mostly noise.

Where authors usually get this wrong

The common misses are:

  • centering strategy around an unofficial percentage
  • treating strong oncology science as automatically broad clinical fit
  • overestimating what early-phase or lightly validated biomarker work can do here
  • confusing society prestige with a destination for any good cancer paper

Those are fit problems before they are rate problems.

What to use instead of a guessed percentage

If you are deciding whether to submit, these pages are more useful than an unofficial rate:

Together, they tell you whether the paper is broad enough for a flagship oncology readership, whether another top oncology venue is cleaner, and whether the manuscript really deserves this tier.

Practical verdict

The honest answer to "what is the Annals of Oncology acceptance rate?" is that there is no strong official number you should treat as exact.

The useful answer is:

  • yes, the journal is highly selective
  • no, a guessed percentage is not the right planning tool
  • use clinical consequence, evidence maturity, and broad oncology relevance instead

If you want help pressure-testing whether the paper is really broad enough for this tier before submission, a free Manusights scan is the best next step.

  1. Is Annals of Oncology a good journal, Manusights.
  2. Annals of Oncology journal profile, Manusights.
References

Sources

  1. 1. Annals of Oncology journal home, Elsevier / ESMO.
  2. 2. Annals of Oncology guide for authors, Elsevier.
  3. 3. ESMO Clinical Practice Guidelines, ESMO.

Reference library

Use the core publishing datasets alongside this guide

This article answers one part of the publishing decision. The reference library covers the recurring questions that usually come next: how selective journals are, how long review takes, and what the submission requirements look like across journals.

Open the reference library

Before you upload

Want the full journal picture?

Scope, selectivity, what editors want, common rejection reasons, and submission context, all in one place.

These pages attract evaluation intent more than upload-ready intent.

Anthropic Privacy Partner. Zero-retention manuscript processing.

Internal navigation

Where to go next

Open Journal Guide